Welcome to our dedicated page for Haemonetics Mass news (Ticker: HAE), a resource for investors and traders seeking the latest updates and insights on Haemonetics Mass stock.
Haemonetics Corporation (NYSE: HAE) delivers vital blood and plasma management solutions to healthcare providers worldwide. This page serves as the definitive source for official company announcements, financial updates, and innovation milestones.
Access timely updates on earnings reports, regulatory clearances, and strategic partnerships that shape HAE's leadership in medical technology. Investors will find press releases covering product launches like advanced diagnostic systems, operational expansions, and initiatives enhancing transfusion safety standards.
Our curated news collection helps stakeholders monitor developments across HAE's three core segments: plasma collection technologies, blood center optimization tools, and hospital transfusion management systems. Bookmark this page for direct access to filings, executive commentary, and progress updates on life-saving healthcare solutions.
Haemonetics Corporation (NYSE: HAE) announced Lloyd E. Johnson's election to its Board of Directors and the appointment of Ellen Zane as the new independent Chair. Johnson, a seasoned finance leader with over 35 years of experience, previously held senior roles at Accenture and Delphi Automotive. Zane succeeds Richard Meelia, who retired following the 2021 Annual Meeting. This leadership transition aims to bolster Haemonetics' strategies for enhancing shareholder value.
Haemonetics Corporation (NYSE: HAE) announced it will release its first quarter fiscal year 2022 financial results on August 11, 2021, at 6:00 am EDT. Following this, a conference call will take place at 8:00 am EDT on the same day to discuss the results and answer questions. Investors can access the call via a toll-free number or through an online webcast. A replay will be available for one year starting from August 11, 2021, at 11:00 am EDT.
Haemonetics Corporation (NYSE: HAE) revealed its financial results for the fourth quarter of fiscal 2021, which ended on April 3, 2021. The results can be accessed on the company's Investor Relations website. Following the release, a conference call and webcast will be held on May 13, 2021, at 8:00 a.m. ET, allowing investors to engage with management and learn more about the results. The company’s offerings support healthcare improvements in blood and plasma collection, surgical services, and hospital transfusions. Detailed earnings information is also available through direct links provided in the announcement.
Haemonetics Corporation (NYSE: HAE) announces the publication of full results from the IMPACT trial in the journal TRANSFUSION. This multicenter study analyzed plasma collection methods involving 3,443 donors and 23,137 donations. The trial compared NexSys PCS® with YES® Technology and its Persona® Technology, achieving an 8.2% increase in plasma yield without compromising safety. The NexSys PCS® system with Persona® received FDA clearance in 2020. Plasma is vital for therapies for conditions like hemophilia and primary immunodeficiency, affecting approximately 750,000 patients across North America and Europe.
Haemonetics Corporation (NYSE: HAE) will release its fourth quarter and fiscal year 2021 financial results on May 13, 2021, at 6:00 am EDT. An investor conference call will follow at 8:00 am EDT to discuss the results. Interested participants can join the call via a toll-free number for U.S. and Canada or an international line, with a required conference ID of 8694785. A live webcast will also be available on the company's investor relations website, and a replay will be accessible for one year starting at 11:00 am EDT on the same day.
Haemonetics Corporation (NYSE: HAE) announced that CSL Plasma will not renew their Supply Agreement for PCS2® Plasma Collection System devices in the U.S., effective June 2022. This decision, driven by CSL's internal strategy, will affect approximately $117 million in revenue, which is 11.8% of Haemonetics' total revenue. The company anticipates a $25 million impairment charge and an additional $7 million in expenses in Q4 FY2021. Despite this, Haemonetics remains committed to supporting CSL in other markets and expects continued growth in U.S. plasma collections.
Haemonetics Corporation (NYSE: HAE) has priced a private offering of $435 million aggregate principal amount of 0.00% Convertible Senior Notes due March 2026. This offering, increased from a previous $425 million, is set to close on March 5, 2021. The notes will not bear regular interest and are convertible into common stock at an initial price of approximately $175.34, a 40% premium over the last reported sale. Haemonetics estimates net proceeds of about $423.3 million, for debt reduction and other corporate purposes.
Haemonetics Corporation (NYSE: HAE) announced a private offering of $425 million in Convertible Senior Notes due 2026. The offering is subject to market conditions and is targeted at qualified institutional buyers. An additional $63.75 million may also be offered. The notes will be unsecured and allow conversion into cash or stock. Proceeds will be used for capped call transactions and to reduce existing debt. However, there are risks associated with market conditions and the effectiveness of the capped call transactions.
Haemonetics Corporation (NYSE: HAE) announced that Chris Simon, the President and CEO, will present at the Jefferies Plasma Summit on March 11, 2021, at 10:45 a.m. ET. The presentation will be accessible live via webcast, with a replay available for one month. Haemonetics is focused on delivering innovative medical products and solutions, primarily in blood and plasma collection, surgical services, and hospital transfusions.
FAQ
What is the current stock price of Haemonetics Mass (HAE)?
What is the market cap of Haemonetics Mass (HAE)?
